Clinical data | |
---|---|
Other names | GSK2248761; GSK2248761A; IDX-12899; IDX-899 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H17ClN3O3P |
Molar mass | 413.80 g·mol−1 |
3D model ( JSmol) | |
| |
|
Fosdevirine is an experimental antiviral agent of the non-nucleoside reverse transcriptase inhibitor class that was studied for potential use in the treatment of HIV-AIDS. [1] [2]
It was discovered by Idenix Pharmaceuticals and was being developed by GlaxoSmithKline and ViiV Healthcare, but it has now been discontinued [3] [4] due to unexpected side effects. [5]
Highest Development Phases: Discontinued, HIV-1 infections
GSK2248761 is no longer in clinical development.
Clinical data | |
---|---|
Other names | GSK2248761; GSK2248761A; IDX-12899; IDX-899 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H17ClN3O3P |
Molar mass | 413.80 g·mol−1 |
3D model ( JSmol) | |
| |
|
Fosdevirine is an experimental antiviral agent of the non-nucleoside reverse transcriptase inhibitor class that was studied for potential use in the treatment of HIV-AIDS. [1] [2]
It was discovered by Idenix Pharmaceuticals and was being developed by GlaxoSmithKline and ViiV Healthcare, but it has now been discontinued [3] [4] due to unexpected side effects. [5]
Highest Development Phases: Discontinued, HIV-1 infections
GSK2248761 is no longer in clinical development.